David Cluck, PharmD, BCPS, AAHIVP

home / authors / david-cluck-pharmd-bcps-aahivp

Articles

Site Logo

Guidelines to Caring for Patients With Sepsis: Promise or Progress?

Jessica Burchette, PharmD, BCPS;David Cluck, PharmD, BCPS, AAHIVP
August 8th 2017

Care continues to improve; however, drug-resistant pathogens and a lack of new agents to treat these infections remain a constant challenge.

Read More

Site Logo

Risks Associated With Direct-Acting Antivirals—Smoke or Fire?

Desirae Lindquist, PharmD, BCPS;David Cluck, PharmD, BCPS, AAHIVP
May 9th 2017

Should clinicians be extra vigilant when deciding who receives antiviral therapy, or are the adverse effects few and infrequent?

Read More

Latest Updated Articles

Concerns Over Mosquito-Borne Illness Causes Massachusetts Town to Create Curfew for Parks, Spraying in Counties
Published: August 27th 2024 | Updated: August 28th 2024
Concerns Over Mosquito-Borne Illness Causes Massachusetts Town to Create Curfew for Parks, Spraying in Counties
A Passion for Infectious Disease Education and Communication
Published: June 16th 2025 | Updated: June 23rd 2025
A Passion for Infectious Disease Education and Communication
Geographic and Demographic Variations in Hepatitis C Mortality
Published: June 17th 2025 | Updated: June 23rd 2025
Geographic and Demographic Variations in Hepatitis C Mortality
Psychiatric Symptoms Emerging Years After Infections Like Lyme and Tick-Borne Infections
Published: June 18th 2025 | Updated: June 23rd 2025
Psychiatric Symptoms Emerging Years After Infections Like Lyme and Tick-Borne Infections
FDA Approves Gilead’s Twice-Yearly Injectable Lenacapavir (Yeztugo) for HIV Prevention
Published: June 18th 2025 | Updated: June 23rd 2025
FDA Approves Gilead’s Twice-Yearly Injectable Lenacapavir (Yeztugo) for HIV Prevention
Dual-Targeting miRNAs Identified as Potential Therapeutics Against HCV and BVDV
Published: June 19th 2025 | Updated: June 23rd 2025
Dual-Targeting miRNAs Identified as Potential Therapeutics Against HCV and BVDV
© 2025 MJH Life Sciences

All rights reserved.